Download PDF
TumorDiagnostik & Therapie 2017; 38(08): 491-495
DOI: 10.1055/s-0043-117822
Schwerpunkt Tumoren der Speiseröhre und des Magens
© Georg Thieme Verlag KG Stuttgart · New York

Multimodale Therapie des fortgeschrittenen Ösophaguskarzinoms

Peter Ebeling
,
Udo Vanhoefer
Further Information

Publication History

Publication Date:
11 October 2017 (online)

Also available at
    Permissions and Reprints

Die Behandlung der Ösophaguskarzinome stellt auch heute noch eine erhebliche therapeutische Herausforderung dar. Mit der multimodalen Therapie können die Therapieergebnisse der lokal fortgeschrittenen Ösophaguskarzinome deutlich verbessert werden.
 

  • Literatur

  • 1 Porschen R, Buck A, Fischbach W. et al. S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus (Langversion 1.0 September 2015, AWMF-Registernummer: 021/023OL). Z Gastroenterol 2015; 53: 1288-1347
    Thieme ConnectPubMedSearch in Google Scholar
  • 2 Sjoquist KM, Burmeister BH, Smithers BM. et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-692
    CrossrefPubMedSearch in Google Scholar
  • 3 Van Hagen P, Hulshof MC, van Lanschot JJ. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084
    CrossrefPubMedSearch in Google Scholar
  • 4 Berger AC, Farma J, Scott WJ. et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23: 4330-4337
    CrossrefPubMedSearch in Google Scholar
  • 5 Mariette C, Dahan L, Mornex F. et al. Surgery alone vs. chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol 2014; 32: 2416-2422
    CrossrefPubMedSearch in Google Scholar
  • 6 Stahl M, Stuschke M, Lehmann N. et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-2317 ; Erratum in: J Clin Oncol 2006; 24: 531
    CrossrefPubMedSearch in Google Scholar
  • 7 Cunningham D, Allum WH, Stenning SP. et al. Perioperative Chemotherapy vs. Surgery Alone for Resectable Gastroesophageal Cancer. N Engl J Med 2006; 355: 11-20
    CrossrefPubMedSearch in Google Scholar
  • 8 Ychou M, Boige V, Pignon JP. et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-1721
    CrossrefPubMedSearch in Google Scholar
  • 9 Stahl M, Walz MK, Stuschke M. et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27: 851-856
    CrossrefPubMedSearch in Google Scholar
  • 10 Al-Batran SH, Homann N, Schmalenberg H. et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) vs. epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. J Clin Oncol 2017; 35 (suppl 15): abstr 4004
    CrossrefPubMedSearch in Google Scholar